TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer’s Disease Treatment

FOSTER CITY, Calif., March 14, 2023 /PRNewswire/ -- TrueBinding, Inc.— a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and other disease areas with great unmet needs— announced today that the company has been granted a Type...

Click to view original post